In line with this, β-AR agonist treatment is associated with increased mortality in HF (31, 32) and β-AR blocker treatment can reduce cardiac arrhythmias and sudden cardiac death in HF (35). Here, ADRB2 is linked to chronic obstructive pulmonary disease.